Last reviewed 2026-04-20 · How we verify

Nafronyl (naftidrofuryl)

Nafronyl (generic name: naftidrofuryl) is a naftidrofuryl drug. It is currently in unknown development for Cerebrovascular disease, Chronic Occlusive Peripheral Arterial Disease.

Nafronyl works by interacting with the 5-hydroxytryptamine receptor 2A to improve blood flow and reduce vascular resistance.

Nafronyl (naftidrofuryl) is a small molecule drug that targets the 5-hydroxytryptamine receptor 2A. It is used to treat cerebrovascular disease and chronic occlusive peripheral arterial disease. The commercial status of nafronyl is unclear, but it is not FDA-approved. Key safety considerations include its short half-life of 1.35 hours. Nafronyl is a member of the naftidrofuryl drug class.

At a glance

Mechanism of action

Imagine your blood vessels are like roads in your body. Nafronyl helps to widen these roads, making it easier for blood to flow and reach the areas that need it. This can help to reduce the risk of stroke and improve symptoms of peripheral artery disease.

Approved indications

• Cerebrovascular disease
• Chronic Occlusive Peripheral Arterial Disease

Common side effects

• Acute kidney injury
• Hyperkalaemia
• Lactic acidosis

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Nafronyl CI brief — competitive landscape report
• Nafronyl updates RSS · CI watch RSS
• portfolio CI

Frequently asked questions about Nafronyl

Related

• Drug class: All naftidrofuryl drugs
• Target: All drugs targeting 5-hydroxytryptamine receptor 2A
• Manufacturer: — full pipeline
• Therapeutic area: All drugs in Cardiovascular
• Indication: Drugs for Cerebrovascular disease
• Indication: Drugs for Chronic Occlusive Peripheral Arterial Disease

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing